4 results
1) The BioNIR is non-inferior to the Resolute for the primary clinical endpoint of target lesion failure (TLF) (defined as the composite of cardiac death, target vessel-related MI, or ischemia-driven TLR) at 12 months2/ The BioNIR is non-inferior to…
Primary objective: To evaluate local implementation, safety, feasibility and efficacy of temporary RV support with the Impella RP circulatory support deviceSecondary objective: -To evaluate the effect of temporary RV support on several clinical and…
The BioNIR is non-inferior to the Resolute for the primary angiographic of in-stent late loss at 6 months
This is a research study. The purpose of this study is to test if the investigational medicinal product S48168 (ARM210) is safe and effective when given to patients diagnosed with CPVT1. Primairy objective:To assess the effect of S48168 (ARM210) on…